To make this website work, we log user data. By using Shephard's online services, you agree to our Privacy Policy, including cookie policy.

×
Open menu Search

Challenger 3 upgrade includes three phases but ammo requirements remain unclear

21st April 2022 - 14:00 GMT | by Christopher F Foss in London

RSS

Challenger 2 MBT demonstrator armed with latest Rheinmetall 120mm L55A1 smoothbore gun plus new Thales commanders and gunner's stabilised sights. (Photo: RBSL)

There are three distinct phases to the Challenger 3 MBT upgrade plan for the British Army, but the MoD is still considering its 120mm ammunition options.

RBSL (a JV between Rheinmetall and BAE Systems Land) has confirmed that the British Army’s Challenger 3 MBT Life Extension Programme (LEP) will comprise three phases with an expected in-service date of 2027.

The first phase, now underway, covers the building of six pre-series Challenger 3 MBTs at the RBSL facility in Telford.

This will be followed by Phase 2 LRIP of a further 18 units, with Phase 3 being full-rate production of 203 tanks.

The end result will be sufficient to equip two regiments of the Royal Armoured Corps (RAC) plus vehicles for training and reserve.

There

Already have an account? Log in

Want to keep reading this article?

Read this Article

Get access to this article with a Free Basic Account

  • Original curated content, daily across air, land and naval domains
  • 2 free stories per week
  • Daily news round-up email service
  • Access to all Decisive Edge email newsletters
Create account

Unlimited Access

Access to all our premium news as a Premium News 365 Member. Corporate subscriptions available.

  • Original curated content, daily across air, land and naval domains
  • 14-day free trial (cancel at any time)
  • Unlimited access to all published premium news
Start your free trial
Christopher F Foss

Author

Christopher F Foss


Christopher F Foss is an internationally recognised authority on armoured fighting vehicles, artillery and other weapon systems, …

Read full bio

Share to

Linkedin